Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 6:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Conditions
Major Depressive Disorder
Interventions
CERC-301, Placebo
Drug · Other
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Culver City, California + 21 more
Conditions
22q11.2 Deletion Syndrome
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
COVID-19 Pneumonia, Acute Lung Injury, ARDS
Interventions
CERC-002, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Newport Beach, California • Ft. Pierce, Florida • West Palm Beach, Florida + 8 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
NFC-1, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Attention-deficit Hyperactivity Disorder (ADHD)
Interventions
NFC-1
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
12 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 2 Interventional Results available

TARGTEPO Treatment for Anemia in PD US Trial

NCT02468414
Conditions
Anemia of End Stage Renal Disease
Interventions
MDGN201 TARGTEPO
Biological
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Healthy
Interventions
FP01
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Major Depressive Disorder
Interventions
CERC-301, Placebo
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Newport Beach, California • Alpharetta, Georgia • Chicago, Illinois + 10 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Wayne, Pennsylvania
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AEVI-001, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Wayne, Pennsylvania
Conditions
Chronic Refractory Cough
Interventions
FP01, placebo
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
8
States / cities
San Jose, California • Largo, Florida • Miami, Florida + 5 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
AEVI-001, Placebo
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Wayne, Pennsylvania
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
MDGN-002
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Hialeah, Florida • New Port Richey, Florida • Atlanta, Georgia + 9 more
Conditions
Non-Eosinophilic Asthma
Interventions
AVTX-002, Placebo
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
24
States / cities
Tucson, Arizona • Sacramento, California • Walnut Creek, California + 20 more
Conditions
Multiple Myeloma
Interventions
AEVI-007
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Sacramento, California • West Hollywood, California • Lake Mary, Florida + 4 more
Conditions
Lymphatic Malformation
Interventions
CERC-006
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years to 31 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Aurora, Colorado • Atlanta, Georgia • Cincinnati, Ohio
Conditions
Hidradenitis Suppurativa
Interventions
AVTX-009 Regimen 1, AVTX-009 Regimen 2, Placebo
Drug
Lead sponsor
Avalo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
36
States / cities
Scottsdale, Arizona • Tucson, Arizona • Northridge, California + 31 more
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Wilmington, Delaware
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
NFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg, NFC-1 800 mg
Drug
Lead sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Industry
Eligibility
6 Years to 17 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Maitland, Florida • Miami, Florida • Las Vegas, Nevada